Overall verdict
Neutral
3.8/10
1-year performance
-48.03%
Score breakdown
Down 48.0% over 1 year, 1% of the 52-week range.
Strongest: Growth 8.6/10. Weakest: Shareholder return 0.0/10.
6 analysts, target +14.3% vs the price.
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis ;
OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD) ; and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult.
In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nasdaq
United States
CEO
Shankar Musunuri
Founded
2013
Employees
116
Revenue / employee
38 043 USD
Next earnings
November 6, 2026 (estimated)
Institutional holders
- BlackRock, Inc.7.96%
- STATE STREET CORP6.33%
- VANGUARD CAPITAL MANAGEMENT LLC4.24%
- MILLENNIUM MANAGEMENT LLC4.11%
- GEODE CAPITAL MANAGEMENT, LLC2.62%
- RTW INVESTMENTS, LP1.97%
- UBS Group AG1.53%
- Ikarian Capital, LLC1.17%
- GMT Capital Corp1.03%
- Other institutions11.96%
- Rest of the register57.08%
149 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
2.73 USD
52-week low
0.78 USD
1-year performance
-48.03%
Declining
Year-to-date performance
-41.54%
Declining
Drawdown
-70.82%
Major drawdown
Position in the 52-week range
1% of range
The company loses 1786.3% of its revenue, ROIC -704.2%, ROE 1211.7%.
Net margin
-1786.27%
Negative
Sector -223.73%|S&P 13.15%
Gross margin
—
Return on equity (ROE)
1211.66%
Exceptional
Sector -58.80%|S&P 16.61%
Return on invested capital (ROIC)
-704.24%
Negative
Free cash flow margin (FCF)
-1332.36%
Negative
Revenue to net income
Growth
8.6/10Revenue up 8.4% over 1 year, 152.9% a year over 5.
Revenue (trailing 12 months)
4.6M USD
Revenue growth (1y)
8.38%
Hyper-growth
Revenue growth (3y)
77.37%
Strong
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
0.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 11.4x|S&P 24.1x
Forward P/E (adjusted)
—
N/A (loss)
EV / EBITDA
—
N/A (loss)
Sector 14.4x|S&P 15.2x
PEG
—
Sector 1.09|S&P 0.90
Market cap
270M USD
Financial strength
3.8/10Cash covers 113.7% of the debt.
Net debt / EBITDA
—
Gearing (net debt / equity)
—
Cash
100M USD
Cash / market cap
37.11%
Very solid
Cash / total debt
113.71%
Net cash
Interest coverage
-8.2x
Stretched
Net debt
-12.1M USD
Equity
-16.6M USD
Closed daily candles, 2 years
Last close on October 21, 2026: 0.82 USD
- MM200.95
- MM501.12
- MM2001.46
- RSI 1430.0
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-2.89%
200-day average slope, 3 months
-5.21%
50-day average slope, 1 month
-11.47%
Price structure
Lower lows
Bullish RSI divergence
No
20-day volatility
3.28 % per day
Volatility change
-20.17%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | -0.26 (6) | -0.24 (3) | 5 (6) | — | -87 (4) |
| 2027 | -0.27 (4) | -0.25 (3) | 6 (4) | — | -95 (4) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of October 15, 2026.
Same sub-industry: 781 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AGEN | 5.6 | 4.9 | 289M USD | 2.4x | 69.3 % | 34.4 % | -11.7 % | 6.7x | -34.1 % | 44.8 % | ||
| 2 | SRZN | 5.5 | 4.3 | 298M USD | Not meaningful (loss) | -3042.9 % | 408.6 % | — | 2.2x | -11.8 % | 87.6 % | ||
| 3 | 6915 | 4.9 | 4.9 | 285M USD | — | — | 6.7 % | — | -0.7x | — | -7.8 % | ||
| 4 | PRLD | 4.7 | 3.5 | 291M USD | Not meaningful (loss) | -269.7 % | 73.4 % | -50.5 % | 2.0x | -11.4 % | 182.9 % | ||
| 5 | BNTC | 4.4 | N/A | 297M USD | Not meaningful (loss) | — | — | -33.1 % | 3.5x | -5.9 % | -46.2 % | ||
| 6 | OCGN | 3.8 | 3.1 | 270M USD | Not meaningful (loss) | -1786.3 % | 8.4 % | -704.2 % | — | -22.6 % | -48.0 % | ||
| 7 | NWBO | 3.5 | 4.0 | 281M USD | Not meaningful (loss) | -1736.4 % | 535.4 % | 275.6 % | -1.3x | -17.7 % | -25.0 % | ||
| 8 | IPSC | 3.4 | 1.5 | 292M USD | Not meaningful (loss) | -100.6 % | 1556.8 % | -41.9 % | 0.9x | -30.2 % | 182.2 % | ||
| 9 | XFOR | 3.2 | 3.0 | 298M USD | Not meaningful (loss) | -568.8 % | 346.3 % | -57.6 % | 1.5x | — | -4.4 % |
